Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 8/20 | 0.41 |
| ▸ | PPARG | P37231 | 8/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7312753 | 0.88 | MDM2 (0.39) | PPARGPLA2G2AGRIN1GRIN2B | |
| Trifluoroacetic Acid SCHEMBL7316949 | 0.87 | ABCB11 (0.40) | PLA2G2AGRIN1GRIN2B | |
| Trifluoroacetic Acid SCHEMBL7315970 | 0.83 | CCR2 (0.41) | PLA2G2AGRIN1GRIN2B | |
| Trifluoroacetic Acid SCHEMBL7314734 | 0.83 | AR (0.38) | PPARGPLA2G2A | |
| Trifluoroacetic Acid SCHEMBL7585777 | 0.78 | EGFR (0.46) | ICMTPPARGPLA2G2A | |
| Trifluoroacetic Acid SCHEMBL7397464 | 0.72 | PTGDR2 (0.37) | — | |
| Trifluoroacetic Acid SCHEMBL7317213 | 0.70 | EGFR (0.56) | ICMTPPARG | |
| SCHEMBL6091159 | 0.69 | PPARG (0.65) | ICMTPPARGF2RL3 | |
| SCHEMBL6093344 | 0.67 | PPARG (0.65) | ICMTPPARGPLA2G2AF2RL3 | |
| SCHEMBL5772496 | 0.67 | PPARG (0.57) | ICMTPPARGPLA2G2AGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | claimed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | claimed |
| US-20020004198-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2002-01-10 | — | — | US | disclosed |
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | CTSL, MMP8, SERPINB1 | ICMT 1459/4885PPARG 2889/4885PLA2G2A 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.